Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07710612 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Study of ABSK043 Combined With Osimertinib

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer
Trial Details
NCT Number NCT07710612
Lead Sponsor Abbisko Therapeutics Co, Ltd
Collaborators: AstraZeneca
Conditions Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov